Extraordinary extrahaematological manifestations of chronic myelomonocytic leukaemia

Lancet. 2020 Sep 19;396(10254):853. doi: 10.1016/S0140-6736(20)31905-X.

Authors

Ioanna E Stergiou¹, Panagiotis Christoforou², Georgia Sypsa³, Spyridon Skoufias⁴, Dionysios Mitropoulos⁴, Athanasios G Tzioufas², Michael Voulgarelis²

Affiliations

¹ Pathophysiology Department, School of Medicine, National and Kapodistrian University of Athens, Laikon Hospital, Athens, Greece. Electronic address: [email protected].
² Pathophysiology Department, School of Medicine, National and Kapodistrian University of Athens, Laikon Hospital, Athens, Greece.
³ Radiology Department, Laikon Hospital, Athens, Greece.
⁴ 1st Department of Urology, School of Medicine, National and Kapodistrian University of Athens, Laikon Hospital, Athens, Greece.

PMID: 32950091
DOI: 10.1016/S0140-6736(20)31905-X

No abstract available

Publication types

Case Reports
Video-Audio Media

MeSH terms

Adrenal Cortex Hormones / therapeutic use
Aged
Antineoplastic Agents, Alkylating / therapeutic use
Biopsy, Needle / methods
Bone Marrow / pathology*
Cyclophosphamide / therapeutic use
Facial Paralysis / diagnosis
Facial Paralysis / etiology*
Female
Hematoma / etiology
Humans
Immunoglobulins, Intravenous / therapeutic use
Kidney / blood supply
Kidney / diagnostic imaging
Kidney / pathology
Knee Joint / pathology
Leukemia, Myelomonocytic, Chronic / complications
Leukemia, Myelomonocytic, Chronic / pathology*
Leukemia, Myelomonocytic, Chronic / therapy
Male
Nephrectomy / methods
Polyarteritis Nodosa / drug therapy
Polyarteritis Nodosa / pathology
Stomatitis, Aphthous / etiology
Synovitis / etiology
Tongue Diseases / pathology
Wrist Joint / pathology

Substances

Adrenal Cortex Hormones
Antineoplastic Agents, Alkylating
Immunoglobulins, Intravenous
Cyclophosphamide